SCHEMBL27449488

SCHEMBL27449488

C[SH](C)c1c[nH]c2ccc(Cl)cc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 1/20 0.55
HTR2A P28223 3/20 0.53
TRPM8 Q7Z2W7 1/20 0.53
F7 P08709 1/20 0.51
F3 P13726 1/20 0.51
SLC6A4 P31645 2/20 0.50
NR4A2 P43354 1/20 0.49
IDO1 P14902 4/20 0.47
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47
TUBA1A Q71U36 1/20 0.47
TUBA1C Q9BQE3 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3180061 0.77 F7 (0.56) GPR84HTR2ATRPM8F7F3
SCHEMBL4086846 0.76 GPR84 (0.58) GPR84HTR2ATRPM8F7F3
SCHEMBL17982265 0.76 GPR84 (0.58) GPR84HTR2ATRPM8F7F3
SCHEMBL38663621 0.75 GPR84 (0.62) GPR84HTR2ATRPM8F7F3
SCHEMBL12464834 0.73 HTR2A (0.71) GPR84HTR2ATRPM8SLC6A4IDO1
SCHEMBL3780100 0.72 GPR84 (0.58) GPR84HTR2ATRPM8F7F3
SCHEMBL17439076 0.72 F7 (0.59) GPR84HTR2ATRPM8F7F3
SCHEMBL28077797 0.72 GPR84 (0.58) GPR84HTR2ATRPM8F7F3
SCHEMBL30415771 0.72 GPR84 (0.58) GPR84HTR2ATRPM8F7F3
SCHEMBL208040 0.72 GPR84 (0.58) GPR84HTR2ATRPM8F7F3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 GPR84 4777/4885HTR2A 3605/4885TRPM8 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.